主要がん部位による静脈性血栓栓症のアウトカムの変動: RIETE レジストリ分析
Javier Trujillo-Santos1, Cihan Ay2, Behnood Bikdeli3
1Department of Internal Medicine, Hospital General Universitario Santa Lucía, Cartagena, Spain; UCAM - Universidad Católica San Antonio de Murcia, Guadalupe, Spain.
JACC. Advances
|August 23, 2025
まとめ
静脈血栓塞栓症 (VTE) のがん患者は再発や出血のリスクが高く,がんの種類によって著しく異なる. これらのサイト特有のリスクに基づいて,個別化された抗凝固戦略が推奨されます.
科学分野:
- 腫瘍学
- 血液学
- 臨床研究
背景:
- 癌に関連した静脈血栓塞栓症 (VTE) の患者は,VTEの再発および出血のリスクが高くなります.
- これらのリスクに対する癌部位の影響はよく定義されていません.
研究 の 目的:
- 様々な癌部位における90日間の再発性VTEまたはVTE関連死亡および大出血のリスクを比較する.
- 静脈血栓炎を患っているがん患者のための個別化された抗凝固策を策定する.
主な方法:
- RIETEの登録から,がんとVTEを患った18,660人の患者の分析.
- 多変数CoxモデルとFine-Grayの競合するリスク分析を用いた.
- 感受性分析には,傾向スコアのマッチングとがん部位によるサブグループ層化が含まれていた.
主要な成果:
- がん関連の血栓症の患者は,がんでない患者と比較して,有意に高いVTEリスク (aHR: 2.54) と大出血 (aHR: 1.40) を有していた.
- 肺癌と臓癌は血栓形成のリスクが最も高く,胃腸癌,尿道癌,臓癌は出血のリスクが最も高かった.
- 結果は,傾向スコアマッチングを含む感受性分析において一貫していました.
結論:
- がん患者における静脈血栓塞栓症と出血のリスクは,原発がんの部位によって大きく異なります.
- これらの発見は,個々の癌の種類に基づいて調整された抗凝固管理の必要性を強調しています.
関連する概念動画
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
01:30Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K